UY37342A - COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE - Google Patents

COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE

Info

Publication number
UY37342A
UY37342A UY0001037342A UY37342A UY37342A UY 37342 A UY37342 A UY 37342A UY 0001037342 A UY0001037342 A UY 0001037342A UY 37342 A UY37342 A UY 37342A UY 37342 A UY37342 A UY 37342A
Authority
UY
Uruguay
Prior art keywords
inhibitor
bcl
combination
pharmaceutical compositions
mcl1
Prior art date
Application number
UY0001037342A
Other languages
Spanish (es)
Inventor
Olivier Geneste
Leticia Maragno Ana
Andrew Wei
Audrey Claperon
Dale Porter
Donia Moujalled
Ensar Halilovic
Erick Morris
Giovanna Pomilio
Heiko Maacke
Prakash Mistry
Sneha Sanghavi
Youzhen Wang
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of UY37342A publication Critical patent/UY37342A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una combinación que comprende un inhibidor de BCL-2 y un inhibidor de MCL1, y composiciones y usos de ésta.A combination comprising a BCL-2 inhibitor and an MCL1 inhibitor, and compositions and uses thereof.

UY0001037342A 2016-07-22 2017-07-21 COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE UY37342A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16180918 2016-07-22
EP16306420 2016-10-28
US201762464554P 2017-02-28 2017-02-28
US201762517252P 2017-06-09 2017-06-09

Publications (1)

Publication Number Publication Date
UY37342A true UY37342A (en) 2018-01-31

Family

ID=60993151

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037342A UY37342A (en) 2016-07-22 2017-07-21 COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE

Country Status (4)

Country Link
AU (1) AU2017300738A1 (en)
TW (1) TWI759316B (en)
UY (1) UY37342A (en)
WO (1) WO2018015526A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111818917A (en) 2017-08-15 2020-10-23 艾伯维公司 Macrocyclic MCL-1 inhibitors and methods of use
UY38431A (en) * 2018-10-31 2020-05-29 Servier Lab CYCLODEXTRIN-BASED FORMULATION OF A BCL-2 INHIBITOR
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
TW202315637A (en) 2021-06-11 2023-04-16 美商基利科學股份有限公司 Combination mcl-1 inhibitors with anti-cancer agents
TW202317200A (en) 2021-06-11 2023-05-01 美商基利科學股份有限公司 Combination mcl-1 inhibitors with anti-body drug conjugates
TW202408588A (en) 2022-05-20 2024-03-01 瑞士商諾華公司 Antibody-drug conjugates of antineoplastic compounds and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2986002B1 (en) 2012-01-24 2014-02-21 Servier Lab NOVEL INDOLIZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3008976A1 (en) 2013-07-23 2015-01-30 Servier Lab "NOVEL INDOLIZINE DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM"
FR3008979B1 (en) 2013-07-23 2015-07-24 Servier Lab NOVEL PHOSPHATE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3008975A1 (en) 2013-07-23 2015-01-30 Servier Lab NOVEL PYRROLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3015483B1 (en) 2013-12-23 2016-01-01 Servier Lab NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
JO3474B1 (en) 2014-08-29 2020-07-05 Amgen Inc Tetrahydronaphthalene derivatives that inhibit mcl-1 protein
FR3037957B1 (en) 2015-06-23 2019-01-25 Les Laboratoires Servier NOVEL HYDROXYESTER DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037956B1 (en) 2015-06-23 2017-08-04 Servier Lab NOVEL AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
FR3037958B1 (en) 2015-06-23 2019-01-25 Les Laboratoires Servier NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR3037959B1 (en) 2015-06-23 2017-08-04 Servier Lab NOVEL BICYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

Also Published As

Publication number Publication date
AU2017300738A1 (en) 2019-02-07
TW201806600A (en) 2018-03-01
WO2018015526A1 (en) 2018-01-25
TWI759316B (en) 2022-04-01

Similar Documents

Publication Publication Date Title
UY37342A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
MX2022004304A (en) Apoptosis-inducing agents.
GT201600249A (en) NEW DERIVATIVES OF PIRAZOLO PIRIMIDINA AND ITS USE AS INHIBITORS OF MALT1
CL2016002772A1 (en) Fast-acting insulin compositions
UY36151A (en) ? A PHARMACEUTICAL COMPOSITION THAT INCLUDES A 3-QUINASA DELTA PHOSFOINOSYTIDE INHIBITOR AND A CORTICOSTEROID ?.
UY37560A (en) COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS
CY1124338T1 (en) 3-PHOSPHOGLYCERATE DEHYDROGENATION INHIBITORS AND THEIR USES
CY1122473T1 (en) HIGH DOSE OPTIMIZED MID-SALIZED TABLET
DOP2019000015A (en) COMBINATION OF A BCL-2 INHIBITOR AND AN MCL1 INHIBITOR, USES AND PHARMACEUTICAL COMPOSITIONS OF THESE
CR20180080A (en) COMBINATIONS OF AN OX40 ANTIBODY AND A TLR4 MODULATOR AND USES OF THE SAME
TR201901228T4 (en) Vortioxetine pyroglutamate.
CY1123408T1 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
CO2019007261A2 (en) Combination of an mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof
CL2018001157A1 (en) Formulation of fixed dose combination, eflornithine and sulindac.
CL2018000308A1 (en) Microcapsule compositions comprising pyrimethanil
CU20170134A7 (en) 2-THIOPIRIMIDINONES
MX2020004731A (en) Ezh2 inhibitor combination therapies.
EA201990305A1 (en) COMBINATION OF BCL-2 INHIBITOR AND MCL-1 INHIBITOR, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS
EA201991623A1 (en) COMBINATION MCL-1 INHIBITOR AND TAXANIC COMPOUND, THEIR APPLICATION AND PHARMACEUTICAL COMPOSITIONS
CO2019004796A2 (en) Preparation of pharmaceutical complex comprising amlodipine, losartan and rosuvastatin
ECSP17085737A (en) SOLID DOSAGE FORMS OF PALBOCICLIB
CL2016002351A1 (en) Liquid detergent compositions comprising an alpha-amylase
UA108342U (en) 7-N-BUTYL-8-N, N-DIETHYLAMINOETHYLAMIN-3-METHYLXANTINE SUCCINATE, WHICH HAS DIURETIC AND ANALGETIC ACTION
CO7141421A2 (en) Pharmaceutical formulation that has improved stability